Drugs / Liraglutide
Liraglutide
Drug FDA approvedMarketed as Saxenda, Victoza
GLP-1 receptor agonist·First approved·2010·2 brands
- Registered trials
- 317
- Ongoing
- 16/ 5%
- Completed
- 250
- Indications
- 4
Approved indications by brand
Indications below are grouped by brand, since each brand carries its own label.
| Brand | Indication |
|---|---|
| Saxenda | Chronic weight management in adults and pediatric patients aged 12 years and older with body weight >60 kg and obesity |
| Chronic weight management in adults with overweight and at least one weight-related comorbid condition | |
| Victoza | Adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus |
| Reduce risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease |
Clinical trial landscape
317 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 4 | 80 | 9 | 54 | |
| Phase 3 | 76 | 1 | 66 | |
| Phase 1 | 52 | 1 | 49 | |
| Phase 2 | 47 | 1 | 37 | |
| Unknown | 24 | 1 | 22 | |
| Not applicable | 24 | 1 | 13 | |
| Phase 2/3 | 5 | 0 | 4 | |
| Phase 1/2 | 5 | 1 | 3 | |
| Early Phase 1 | 4 | 1 | 2 | |
| All phases | 317 | 16 | 250 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Glucagon-like peptide-1 (GLP-1) receptor agonism.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.